GlobeNewswire Inc.··NaDesign Therapeutics Reports Positive Four-Week Data for Friedreich Ataxia Treatment
Design Therapeutics announces positive Phase 1/2 data for DT-216P2 showing clinical improvements and biomarker activity in Friedreich ataxia patients.
DSGNclinical trialgene therapy